Vertex Pharmaceuticals (VRTX)
(Delayed Data from NSDQ)
$287.32 USD
+5.53 (1.96%)
Updated Jul 1, 2022 04:00 PM ET
3-Hold of 5 3
C Value A Growth B Momentum A VGM
Price, Consensus and EPS Surprise
VRTX 287.32 +5.53(1.96%)
Will VRTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for VRTX based on the 1-3 month trading system that nearly triples the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for VRTX
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
Should Invesco S&P 500 GARP ETF (SPGP) Be on Your Investing Radar?
VRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
The Zacks Analyst Blog Highlights Apple, NVIDIA, McDonald's, Cisco Systems and Vertex Pharmaceuticals
Other News for VRTX
Teva names new medical chief
Teva appoints Eric Hughes as CMO
Vertex Pharmaceuticals Inc. stock outperforms market on strong trading day
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Marketplace Roundtable - Part 6 - Biotech And Healthcare